Adverse Cutaneous Reactions to Hydroxychloroquine Are More Common in Patients With Dermatomyositis Than in Patients With Cutaneous Lupus Erythematosus

Pelle, Michelle T.; Callen, Jeffrey P.

doi:10.1001/archderm.138.9.1231

Cited by 103 publications

(64 citation statements)

References 4 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The usual precautions regarding antimalarial therapy should be taken, including a careful ophthalmologic examination and follow-up. Patients with dermatomyositis seem to have a greater potential to develop morbilliform drug reactions with hydroxychloroquine, and a pretreatment warning is helpful [18].…”

Section: Course and Treatment Of Cutaneous Lesions Of Dermatomyositismentioning

confidence: 99%

Cutaneous Manifestations of Dermatomyositis and Their Management

Callen

2010

Curr Rheumatol Rep

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Course and Treatment Of Cutaneous Lesions Of Dermatomyositismentioning

confidence: 99%

Cutaneous Manifestations of Dermatomyositis and Their Management

Callen

2010

Curr Rheumatol Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…It appears that patients with DM have a greater potential to develop morbilliform drug reactions with hydroxychloroquine, and a pretreatment warning is helpful [31]. In addition, counseling regarding smoking cessation is essential as the efficacy of hydroxychloroquine appears to be reduced in patients who smoke.…”

Section: Antimalarialsmentioning

confidence: 99%

Dermatomyositis: current and future treatments

Vleugels

Callen

2009

Expert Review of Dermatology

View full text Add to dashboard Cite

“…Trabalhos recentes demonstram tratamento efetivo da doença, [76][77][78][79][80][81][82][83][84][85][86] apresentado no quadro 4.…”

Section: Tratamentounclassified

Dermatomiosite

Ortigosa

Reis

2008

An. Bras. Dermatol.

View full text Add to dashboard Cite

Resumo: Dermatomiosite é doença idiopática inflamatória crônica que afeta a musculatura estriada, a pele e outros órgãos. Apresenta critérios diagnósticos definidos por Bohan & Peter, podendo os pacientes ser classificados em cinco grupos: dermatomiosite juvenil, dermatomiosite primária idiopá-tica, dermatomiosites amiopáticas, dermatomiosite associada a neoplasias e dermatomiosite associada a outras doenças do tecido conectivo. O sexo feminino é mais afetado, e a idade média do diagnósti-co é 40 anos. Manifestações cutâneas são observadas em todos os pacientes. Das alterações sistêmicas, a manifestação muscular mais freqüente é a perda de força proximal, e a manifestação pulmonar mais comum é a pneumopatia intersticial. Podem ser observadas neoplasias durante o seguimento da doença, sendo mais freqüentes nos pacientes acima de 60 anos. A desidrogenase lática é a enzima muscular alterada na maioria dos casos. Para diagnóstico da dermatomiosite, pode ser realizado exame anatomopatológico de biópsia cutânea e biópsia muscular, além de eletroneuromiografia. Os corticóides são a terapia mais utilizada. As causas de óbito mais freqüentes são a neoplasia maligna, a septicemia e a infecção pulmonar.

show abstract

Adverse Cutaneous Reactions to Hydroxychloroquine Are More Common in Patients With Dermatomyositis Than in Patients With Cutaneous Lupus Erythematosus

Cited by 103 publications

References 4 publications

Cutaneous Manifestations of Dermatomyositis and Their Management

Cutaneous Manifestations of Dermatomyositis and Their Management

Dermatomyositis: current and future treatments

Dermatomiosite

Contact Info

Product

Resources

About